Check for updates

# Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With *NPM1* and *FLT3* Mutations

Nigel H. Russell, MD[1]; Charlotte Wilhelm-Benartzi, PhD[2]; Jad Othman, MBBS[3]; Richard Dillon, PhD[3]; Steven Knapper, MD[4]; Leona M. Batten, MSc[2]; Joanna Canham, PhD[2]; Emily L. Hinson, PhD[2]; Sophie Betteridge, PhD[2]; Ulrik Malthe Overgaard, MD[5]; Amanda Gilkes, PhD[4]; Nicola Potter, PhD[3]; Priyanka Mehta, MD[6]; Panagiotis Kottaridis, MD[7]; Jamie Cavenagh, MD[8]; Claire Hemmaway, MD[9]; Claire Arnold, MD[10]; Sylvie D. Freeman, PhD[11]; and Mike Dennis, MD[12]; on behalf of the UK NCRI AML Working Group

## ABSTRACT

**PURPOSE** To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics.

**PATIENTS AND METHODS** One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS).

**RESULTS** There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; *P* = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; *P* < .001) and 3-year event-free survival was higher (57% v 45%; *P* < .001). In patients with an *NPM1* mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; *P* = .005). *NPM1* measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (*P* = .02). Three-year OS was also higher in patients with a *FLT3* mutation (64% v 54%; *P* = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; *P* = .02). There was no difference in outcome according to the number of GO doses, although *NPM1* MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO.

**CONCLUSION** Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with *NPM1* and *FLT3* mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit.

### ACCOMPANYING CONTENT

📎 Appendix

🔗 Data Supplement

🔗 Protocol

View Online Article

## INTRODUCTION

The optimal induction regimen for younger patients with newly diagnosed AML is uncertain, although a 3 + 7 regimen of an anthracycline plus cytosine arabinoside (Ara-C) is regarded as a standard of care.[1] In the Medical Research Council AML15 trial, we observed a higher response rate and reduced relapse in patients treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-Ida) compared with those treated with daunorubicin and Ara-C (DA) with or without etoposide (ADE), but no difference in overall survival (OS).[2] There was

ASCO **Journal** of Clinical Oncology®

## CONTEXT

### Key Objective

To compare a single dose versus fractionated schedule of gemtuzumab ozogamicin (GO) combined with standard or intensified induction chemotherapy (daunorubicin and Ara-C [DA] or fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) in younger adults with AML.

### Knowledge Generated

Fractionated GO did not improve outcomes compared with a single dose. The combination of GO with FLAG-Ida increased myelosuppression but also improved event-free survival (EFS) compared with DA + GO. There was evidence for an overall survival benefit in patients with NPM1 and FLT3 mutations not observed in other molecular subgroups, including core binding factor AML, where excellent outcomes were achieved with DA + GO.

### Relevance (S. Lentzsch)

In the evolving landscape of treating NPM1 and FLT3 mutated AML patients, these data showing that FLAG-Ida + GO significantly improves the 3-year EFS in NPM1 and FLT3 mutated AML are promising. However, additional studies reflecting the current standard of care are needed.*

*Relevance section written by JCO Associate Editor Suzanne Lentzsch, MD, PhD.

more hematologic toxicity with FLAG-Ida, predominately after the second induction course, affecting delivery of consolidation therapy. Nevertheless, patients who received two courses of FLAG-Ida only had promising outcomes.

The AML15 study also demonstrated that the addition of gemtuzumab ozogamicin (GO) at a single dose of 3 mg/m² in induction but not consolidation improved OS.[3] This benefit was seen in patients with favorable and intermediate-risk cytogenetics. A study in older patients conducted by the ALFA group comparing DA with or without GO given in a fractionated schedule (days 1, 4, and 7) and in consolidation showed an improvement in event-free survival (EFS) leading to regulatory approval.[4,5] The survival benefit of GO was confirmed in a meta-analysis of five front-line trials; however, it remained unclear which scheduling was optimal.[6] ALFA0701 also suggested a survival benefit for GO in NPM1-mutated (NPM1^mut) AML, supported by measurable residual disease (MRD) analyses using reverse-transcription quantitative polymerase chain reaction showing that GO increased MRD negativity.[7] Subgroup analyses also suggested a benefit for patients with a FLT3 mutation (FLT3^mut).[8]

The primary aim of the National Cancer Research Institute (NCRI) AML19 trial was to define the optimal induction chemotherapy regimen for younger patients with newly diagnosed AML without known adverse cytogenetics by comparing DA and FLAG-Ida combined with either a single dose or fractionated GO schedule. The fractionated schedule used two doses of GO because of toxicity concerns, particularly with FLAG-Ida, which had previously only been given with a single dose.[3] Secondary aims were to evaluate the impact of these regimens in molecular and cytogenetic subgroups, their effect on MRD clearance, and the benefit of consolidation after two courses of FLAG-Ida + GO.

## PATIENTS AND METHODS

The NCRI AML19 trial (ISRCTN78449203) enrolled 1,498 patients generally age 16-60 years with newly diagnosed de novo or secondary AML or myelodysplastic syndrome (MDS)-EB2, not known to have adverse risk cytogenetics, between November 2015 and November 2020. Older patients (age older than 60 years) could be enrolled if considered fit for intensive therapy. Of patients enrolled, 19 later withdrew consent, leaving 1,479 randomly assigned between FLAG-Ida (n = 738) and DA (n = 741). Hydroxycarbamide was permitted for up to 7 days before treatment initiation. Previous azacytidine was permitted for the treatment of MDS but not of AML. Of the 1,479 patients, 1,033 were also randomly assigned to receive a single dose of GO on D1 (GO1, n = 514) or a fractionated schedule given on D1 and D4 (GO2, n = 519). The remaining patients did not enter the GO randomization either because of contraindication due to abnormal liver function, or because of a transient drug supply interruption.

Patients were designated as high-risk after course 1 if they had refractory disease, on the basis of a validated risk score,[9] or if they had a FLT3-internal tandem duplication (ITD) mutation and unmutated NPM1. After course 2, NPM1^mut patients could be designated HR if they had detectable MRD in the peripheral blood (PB).[10] After a protocol amendment in February 2018, patients without NPM1 mutation who tested MRD-positive in the bone marrow (BM) by flow cytometry (>0.1%) were also designated high-risk.[11] Patients classified as high-risk after course 1 or course 2 were recommended for transplant and

could enter a randomization between CPX-351 and FLAG-Ida but are included in this analysis.

Patients who were not high-risk after cycle 1 received a second course of allocated induction without GO and if not high-risk after course 2 could receive up to two courses of high-dose cytarabine (HDAC) consolidation (3 g/m² twice daily on D1, 3, and 5, reduced to 1.5 g/m² for patients age older than 60 years). Patients in the FLAG-IDA arm who had completed two induction courses could enter a randomization to receive zero, one, or two courses of HDAC. Patients with core binding factor (CBF) AML and those with detectable MRD in the BM, either by flow cytometry or molecular assessment, were excluded from this randomization. No *FLT3* inhibition was used as midostaurin had not been approved when this study commenced.

The trial was approved by the Wales Multicentre Research Ethics Committee 3 (14/WA/1056) and conducted in accordance with the Declaration of Helsinki. Written consent was required for each randomization. A CONSORT diagram is shown in Figure 1. Figure 2 shows treatment schedules and trial schema. All randomizations used a 1:1 ratio. The AML19 study contained a number of other independent randomizations available to patients with specific disease characteristics. This paper reports only on those patients without known adverse karyotype at diagnosis who were randomly assigned between FLAG-Ida + GO and DA + GO; results of other randomizations will be reported separately.

## Statistical Analyses

Primary analyses are by intention-to-treat, and the primary end point of the randomization was OS. End points were defined according to the revised International Working Group criteria.[12] OS was defined as the time from randomization (DA + GO *v* FLAG-Ida + GO) to death from any cause with those still alive censored at the date last seen. Final data cutoff was on May 17, 2022. Relapse-free survival (RFS) was calculated only for patients who achieved complete remission (CR) or CR with incomplete hematological recovery (CRi), and was measured from the date of CR/CRi until the date of relapse or death from any cause. EFS was measured in all patients and was defined as the time from randomization to the occurrence of the first of one of the following events: failure to achieve CR/CRi by end of course 2, relapse, or death from any cause. For the outcomes of OS, RFS, EFS, and CR/CRi achievement, multivariable analyses were adjusted by all stratification variables used at the time of randomization (sex, age group, performance status, baseline white blood cell count, and disease type).

## RESULTS

### Patients

Baseline characteristics are shown in Table 1. The median age was 51.5 years and 149 (14%) were age older than 60 years.

Eighty-eight percent had de novo AML, 7% clinical secondary AML, and 5% MDS-EB2. Cytogenetic risk was favorable in 12%, intermediate in 75%, and adverse in 9%; the remaining had missing data. Of major molecular subgroups, 30% had *NPM1* and 26% *FLT3* ITD or tyrosine kinase domain (TKD) mutations, and 12% had either t(8;21)(q22;q22) or inv(16)(p13.1;q22) and were thus designated CBF AML. After the first cycle, 692 patients received course 2 of allocated induction (348 DA + GO, 344 FLAG-Ida + GO) and 179 were designated high-risk. After the second cycle, 35 patients were designated high-risk on the basis of MRD and 415 proceeded to HDAC consolidation, including 279 initially assigned DA + GO and 136 initially assigned FLAG-Ida + GO (Fig 1). Eighty-five patients entered the post FLAG-Ida consolidation randomization (54 of whom had received FLAG-Ida + GO and 31 FLAG-Ida alone).

### Induction Response

In the comparison of GO1 versus GO2, there was no significant difference in response rates (Data Supplement, Table S1, online only) or survival; so, for comparisons of DA + GO versus FLAG-Ida + GO, results from GO1 and GO2 were combined. Response rate after two courses did not differ between DA + GO and FLAG-Ida + GO, with CR in 86.6% and 87.2% respectively, and overall response rate (CR plus CRi with incomplete count recovery, CRi) of 90.7% versus 93.0% (Table 2). Day 30 and 60 mortality were not different between DA + GO and FLAG-Ida + GO (D30; 2.9% *v* 3.1%; *P* = .83; D60; 4.6% *v* 4.3%; *P* = .80), neither was there a significant difference between GO1 and GO2 (D30; 2.15% *v* 3.3%; *P* = .11; D60; 3.3% *v* 5.6%; *P* = .08).

### Toxicity

Greater hematologic toxicity was seen after the second course of FLAG-Ida when recovery of neutrophils and platelets was significantly delayed (Data Supplement, Table S2). There was no impact of GO dose on count recovery after course 1 for neutrophils (29 *v* 29 days; *P* = .23) or platelets (27 *v* 29 days; *P* = .07) for GO1 and GO2, respectively. The impact of the hematologic toxicity of the second course of FLAG-Ida was to diminish the proportion of patients continuing with HDAC as course 3 (40% of those not high-risk or entering consolidation randomization *v* 83% for DA) and course 4 (27% of the same group compared with 64% for DA).

### Longer-Term Outcomes

Median follow-up by the reverse Kaplan-Meier method was 32 months. There was no difference in relapse between GO1 and GO2 (3-year cumulative incidence of relapse [CIR], 31% *v* 35%; *P* = .24; Data Supplement, Fig S1), neither was there a difference in OS (3-year OS 66% *v* 63%; hazard ratio [HR], 1.16 [95% CI, 0.95 to 1.439]; *P* = .15), EFS (3-year EFS 52% *v* 49%; HR, 1.09 [95% CI, 0.91 to 1.32]; *P* = .09), or death in remission (3-year cumulative incidence of death in remission

**FIG 1.** CONSORT diagram. APL, acute pyomyeloctic leukemia; DA, daunorubicin and Ara-C; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; GO, gemtuzumab ozogamicin; HDAC, high-dose cytarabine; LFT, liver function tests.

**FIG 2.** Trial schema and treatment protocols. APL, acute promyelocytic leukemia; CR, complete remission; DA, daunorubicin and Ara-C; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; G-CSF, granulocyte colony-stimulating factor; GO, gemtuzumab ozogamicin; HDAC, high-dose cytarabine; MRD, measurable residual disease; PB, peripheral blood; ULN, upper limit of normal; WCC, white cell count.

[CIDCR], 9.2% $v$ 9.7%; $P$ = .91), so again further outcome analyses were undertaken with GO doses combined.

FLAG–Ida + GO significantly reduced relapse (3-year CIR, 24% $v$ 41%; $P$ < .001; Table 2; Fig 3). EFS was significantly better with FLAG–Ida + GO compared with DA + GO (3-year EFS, 45% $v$ 57%; HR, 0.73 [95% CI, 0.61 to 0.87]; $P$ < .001) and did not vary by age, sex, performance status, or clinical disease category (Data Supplement, Fig S2), but there was no difference in OS (63% $v$ 66%; HR, 0.92 [95% CI, 0.75 to 1.13]; $P$ = .41; Figs 3A and 3B). This appeared to be consequent to a higher rate of successful salvage therapy for relapsed/refractory disease after DA + GO (Data Supplement, Fig S3). RFS also favored FLAG–Ida + GO (Table 2). CIDCR was greater with FLAG–Ida + GO (3-year CIDCR, 12% $v$ 7.3%; $P$ = .026; Fig 3D). The number of allogeneic transplants performed in CR1 and overall was lower after FLAG–Ida + GO (181 $v$ 197 in CR1; $P$ = .22; and 238 $v$ 278 overall; $P$ = .021; Table 2).

**TABLE 1.** Baseline Patient Characteristics

| Characteristic | DA + GO1, No. (%) | DA + GO2, No. (%) | FLAG-Ida + GO1, No. (%) | FLAG-Ida + GO2, No. (%) |
|---|---|---|---|---|
| Total | 258 (100) | 262 (100) | 256 (100) | 257 (100) |
| Sex | | | | |
| Male | 132 (51) | 134 (51) | 130 (51) | 132 (51) |
| Female | 126 (49) | 128 (49) | 126 (49) | 125 (49) |
| Age group, years | | | | |
| <30 | 24 (9) | 29 (11) | 28 (11) | 23 (9) |
| 30-39 | 38 (15) | 38 (15) | 37 (14) | 35 (14) |
| 40-49 | 54 (21) | 55 (21) | 54 (21) | 55 (21) |
| 50-59 | 103 (40) | 104 (40) | 101 (39) | 106 (41) |
| ≥60 | 39 (15) | 36 (14) | 36 (14) | 38 (15) |
| Type of disease | | | | |
| De novo AML | 227 (88) | 233 (89) | 226 (88) | 228 (89) |
| Secondary AML | 18 (7) | 17 (6) | 17 (7) | 16 (6) |
| High-risk MDS | 13 (5) | 12 (5) | 13 (5) | 13 (5) |
| WBC (×10⁹/L) | | | | |
| <10 | 138 (53) | 143 (55) | 135 (53) | 140 (54) |
| 10 to <50 | 73 (28) | 74 (28) | 73 (29) | 72 (28) |
| 50 to <100 | 32 (12) | 32 (12) | 34 (13) | 31 (12) |
| ≥100 | 15 (6) | 13 (5) | 14 (5) | 14 (5) |
| WHO performance status | | | | |
| Normal activity | 156 (60) | 161 (61) | 154 (60) | 157 (61) |
| Restricted activity | 86 (33) | 86 (33) | 86 (34) | 86 (33) |
| In bed <50% waking hours | 16 (6) | 15 (6) | 16 (6) | 14 (5) |
| *FLT3* ITD mutation | | | | |
| Wild-type | 209 (81) | 209 (80) | 194 (76) | 196 (76) |
| Mutant | 43 (17) | 47 (18) | 54 (21) | 58 (23) |
| No result | 3 (1) | 3 (1) | 3 (1) | 0 (0) |
| *FLT3* TKD mutation | | | | |
| Wild-type | 234 (91) | 240 (92) | 233 (91) | 232 (90) |
| Mutant | 19 (7) | 17 (6) | 15 (6) | 21 (8) |
| No result | 2 (1) | 2 (1) | 3 (1) | 1 (0) |
| *NPM1* mutation | | | | |
| Wild-type | 183 (71) | 179 (68) | 168 (66) | 179 (70) |
| Mutant | 72 (28) | 79 (30) | 82 (32) | 75 (29) |
| No result | 0 (0) | 1 (0) | 1 (0) | 0 (0) |
| Cytogenetics | | | | |
| Normal | 119 (46) | 140 (53) | 109 (43) | 123 (48) |
| Intermediate | 61 (24) | 74 (28) | 74 (29) | 50 (19) |
| Adverse | 39 (15) | 14 (5) | 29 (11) | 35 (14) |
| Core binding factor | 31 (12) | 24 (9) | 33 (13) | 33 (13) |
| No result | 8 (3) | 10 (4) | 9 (4) | 13 (5) |
| Molecular MRD marker | | | | |
| *NPM1* mutation | 74 (29) | 81 (31) | 82 (32) | 76 (30) |
| *RUNX1::RUNX1T1* | 18 (7) | 8 (3) | 14 (5) | 13 (5) |
| *CBFβ::MYH11* | 12 (5) | 16 (6) | 19 (7) | 19 (7) |
| *KMT2A* fusion | 7 (3) | 7 (3) | 13 (5) | 10 (4) |
| Other | 6 (2) | 11 (4) | 8 (3) | 16 (6) |

Abbreviations: DA, daunorubicin and Ara-C; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; GO, gemtuzumab ozogamicin; ITD, internal tandem duplication; MDS, myelodysplastic syndrome; MRD, measurable residual disease; TKD, tyrosine kinase domain.

**TABLE 2.** Comparison of Outcomes Between DA + GO Versus FLAG-Ida + GO

| Outcome | DA + GO | FLAG-Ida + GO | P |
|---|---|---|---|
| Response after cycle 1, No. (%) | | | |
| CR | 343 (66) | 387 (76) | .014 |
| CRi | 60 (11) | 46 (9) | |
| ORR (CR + CRi) | 403 (78) | 433 (85) | |
| Best response after two cycles, No. (%) | | | |
| CR | 449 (87) | 446 (87) | .19 |
| CRi | 20 (3.9) | 29 (5.7) | |
| ORR (CR + CRi) | 469 (91) | 475 (93) | |
| Early mortality, No. (%) | | | |
| Day 30 | 15 (2.9) | 16 (3.1) | .83 |
| Day 60 | 24 (4.6) | 22 (4.3) | .80 |
| Allogeneic transplant, No. (%) | | | |
| Allogeneic transplant at any time | 278 (54) | 238 (46) | .021 |
| Allogeneic transplant in first response[a] | 197 (42) | 181 (38) | .22 |
| Outcomes at 3 years, % | | | |
| OS | 63 | 66 | .41 |
| EFS | 45 | 57 | <.001 |
| RFS | 52 | 64 | .002 |
| CIR | 41 | 24 | <.001 |
| CIDCR | 7.2 | 12 | .026 |

Abbreviations: CIDCR, cumulative incidence of death in remission; CIR, cumulative incidence of relapse; CR, complete remission; CRi, XXX; DA, daunorubicin and Ara-C; EFS, event-free survival; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; GO, gemtuzumab ozogamicin; ORR, overall response rate; OS, overall survival; RFS, relapse-free survival.
[a]Percentage of patients achieving CR/CRi.

## Outcomes in Molecularly Defined Subgroups

Thirty percent of patients (n = 308) were $NPM1^{mut}$ and 26% (n = 275) $FLT3^{mut}$ AML. In a planned exploratory subgroup analysis with no multiplicity adjustments, both an EFS benefit and an OS benefit were observed for FLAG-Ida + GO in patients with $NPM1^{mut}$ (3-year EFS, 52.5% v 70.2%; 3-year OS, 82% v 64%; HR, 0.5 [95% CI, 0.31 to 0.81]; P = .005; Fig 4) and there was no difference in CIDCR by treatment arm (Data Supplement, Fig S4b). The OS benefit for FLAG-Ida + GO was also seen in $FLT3^{mut}$ AML (3-year OS, 64% v 54%; HR, 0.67 [95% CI, 0.45 to 0.99]; P = .047) and was seen with both $FLT3$-ITD and TKD (Data Supplement, Figs S5A and S5B). There was no benefit for GO2 in either $NPM1^{mut}$ or $FLT3^{mut}$ subgroup (Data Supplement, Fig S6). The survival benefit for FLAG-Ida + GO within the $NPM1^{mut}$ subgroup was seen in both $FLT3^{mut}$ and $FLT3^{wt}$ patients without statistically significant evidence of differential benefit on tests for heterogeneity (Fig 4; P = .08). FLAG-Ida + GO increased the number of patients who were MRD− in the PB after course 2 (PBPC2 MRD−, 88% v 77% with DA + GO; P = .02), as well as the number testing MRD− in the BM both after course 2 (56% v 37%; P = .004) and at the end of treatment (70% v 58%; P = .32; Data Supplement, Fig S7a). Among PBPC2 MRD− patients, the BM response was deeper in the FLAG-Ida + GO arm, with 60% also BM MRD− compared with 47% with DA + GO (P = .069; Data Supplement, Fig S7b). The same

trend for a deeper BM MRD response was seen in those who were PBPC2 MRD+. The improved MRD response with FLAG-Ida + GO was seen in both $FLT3^{mut}$ (PBPC2 MRD−, 83% v 68%) and $FLT3^{wt}$ (PBPC2 MRD−, 92% v 82%).

Within the DA + GO arm, GO2 resulted in an increase in the proportion of patients testing PB PC2 $NPM1$ MRD− (84% for GO2 v 69% for GO1; P = .04) but did not improve survival (3-year OS DA + GO2 70%, DA + GO1 74%). For $NPM1^{mut}$ patients who were PBPC2 MRD+, 61% proceeded to transplant in CR and this did not differ by randomization. For these high-risk $NPM1^{mut}$ patients, 3-year OS was 59%, and those randomly assigned to FLAG-Ida + GO had a trend to better survival than those allocated to DA + GO (3-year OS, 74% v 50%; HR, 0.52 [95% CI, 0.17 to 1.57]; Data Supplement, Fig S8). For PBPC2 MRD− patients, outcomes were excellent with both therapies, but here again survival was superior in patients treated with FLAG-Ida + GO (3-year OS, 90% v 78%; HR, 0.43 [95 CI, 0.22 to 0.87]; Data Supplement, Fig S8). There was no heterogeneity in the FLAG-Ida + GO benefit on the basis of MRD response (Data Supplement, Fig S9).

For patients with CBF AML, there was no EFS or OS benefit for FLAG-Ida + GO (3-year EFS, 72% v 77%; HR, 0.84 [95% CI, 0.4 to 1.76]; P = .64 and 3-year OS, 94% v 86%; HR, 2.04 [95% CI, 0.72 to 5.80]; P = .17 for DA + GO v FLAG-Ida + GO, respectively) and there was no benefit for GO2 (3-year OS,

**FIG 3.** (A) OS, (B) EFS, (C) CIR, and (D) CIDCR by randomization arm (DA + GO v FLAG-Ida + GO). CIDCR, cumulative incidence of death in remission; CIR, cumulative incidence of relapse; CR, complete remission; DA, daunorubicin and Ara-C; EFS, event-free survival; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; GO, gemtuzumab ozogamicin; OS, overall survival.

91% GO1 v 89% GO2; HR, 1.67 [95% CI, 0.64 to 4.39]; P = .29). The best outcomes were achieved with DA + GO1 with 3-year OS of 96% (Data Supplement, Fig S10).

## Consolidation

Patients who were in remission after two courses of FLAG-Ida or FLAG-Ida + GO could enter a randomization to receive no further consolidation, one course of HDAC, or two courses of HDAC. In the randomized comparison (n = 85), the demographics of the patients was balanced except fewer patients allocated no consolidation were $NPM1^{mut}$ (Data Supplement, Table S3). When comparing the three arms, there was a significant difference in CIR (P = .033) and RFS (P = .021), with higher relapse in the one course arm but no difference in OS (P = .18) or CIDCR (P = .8; Data Supplement, Fig S11). In an exploratory nonrandomized comparison of treatment delivered in patients who were $NPM1^{mut}$ and PBPC2 MRD– after two courses of FLAG-Ida + GO (n = 115), there was no evidence

that OS or RFS was improved by consolidation (for zero, one, and two cycles of consolidation, respectively; 3-year OS, 90% v 83% v 93%; P = .53; 3-year RFS, 75% v 65% v 81%; P = .14; Data Supplement, Fig S12).

## DISCUSSION

In this large, randomized study, we observed no survival benefit for fractionated over a single dose of GO. FLAG-Ida + GO significantly improved EFS and reduced relapse compared with DA + GO, although with greater myelosuppression and a higher risk of death in remission. These findings are consistent with the NCRI AML15 trial[2] but are in contrast to the results of the NCRI AML18 trial for older adults, where DA + GO2 improved OS. However, in that study, the benefit was restricted to patients age 60-70 years who were transplanted in CR1.[13] Consistent with AML18, we observed superior MRD clearance with fractionated GO2 when combined with DA.

**FIG 4.** (A) OS and (B) EFS in *NPM1*-mutated AML, (C) OS and (D) EFS in *FLT3*-mutated AML, and (E) forest plot of OS in *NPM1*-mutated AML stratified by *FLT3* status. Unadjusted analysis of patients receiving GO1/GO2. Unadjusted analyses with DA as referent and *FLT3* grouping TKD and ITD patients receiving GO1/GO2. DA, daunorubicin and Ara-C; EFS, event-free survival; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; GO, gemtuzumab ozogamicin; HR, hazard ratio; ITD, internal tandem duplication; OS, overall survival; TKD, tyrosine kinase domain.

Although there was no OS benefit for FLAG–Ida + GO, there was evidence of a substantial EFS benefit, and an OS benefit was apparent in patients with *NPM1* and *FLT3* mutations where the treatment was well tolerated with no excess mortality. Of the many driver mutations documented in AML, *NPM1* and *FLT3* are among the most frequent.[14-16] In

this study, OS at 3 years for patients receiving FLAG-Ida + GO was 86% and 62% and in NPM1[mut] and FLT3[mut] disease, respectively, compared with 64% and 54% with DA + GO. For FLT3[mut] patients, the standard of care is DA plus midostaurin,[1] which in the RATIFY trial gave a 3-year survival of 50%,[17] comparable with the 54% seen here with DA + GO without midostaurin. The result with DA + GO is consistent with previous reports of a GO benefit in FLT3[mut] AML[8,18] but given the superior survival observed with FLAG-Ida + GO without a FLT3 inhibitor, studies combining FLAG-Ida + GO with midostaurin are warranted. In this context, we and others have shown that midostaurin can be safely combined with DA + GO,[19,20] and studies with FLAG-Ida + GO are planned. The survival benefit of FLAG-Ida + GO in NPM1[mut] AML was supported by MRD analysis, where patients treated with FLAG-Ida + GO had faster, deeper clearance of NPM1 transcripts than those receiving DA + GO. The AML17 study demonstrated that achievement of PBPC2 MRD negativity was associated with a greatly reduced risk of relapse and death.[10] Importantly, the FLAG-Ida + GO survival benefit in NPM1[mut] patients was independent of FLT3 mutation and PBPC2 MRD status. These findings are consistent with the observed lower BM MRD levels after course 2 with FLAG-Ida + GO regardless of PB MRD. The survival of NPM1[mut] PB PC2 MRD+ patients in AML19 was improved compared with AML17 (where PC2 MRD status was not used to select patients for intensified treatment and early transplantation). Fewer transplants (15% reduction) were performed in the FLAG-Ida + GO arm overall compared with DA + GO, including fewer in CR1, reflecting the application of MRD negativity to guide transplant decisions and the reduced relapse risk with FLAG-Ida + GO.

GO given in combination with intensive chemotherapy has been reported to increase NPM1 MRD negativity.[7,21] Our results are consistent with these findings and emphasize the interaction between GO and the chemotherapy backbone in eliminating MRD in NPM1[mut] AML. Thus, for patients allocated DA chemotherapy, GO2 was more effective than GO1 in reducing MRD, whereas with the more intensive FLAG-Ida regimen, there was no benefit of GO2.

Previous studies have established the benefit of GO in patients with favorable-risk cytogenetics,[3,6] although the ALFA0701 trial included few such patients[4] and the question of the optimal dose and scheduling has been unresolved. We observed no survival benefit for GO2 in this group, neither was there benefit for FLAG-Ida, the best results being achieved with DA + GO1. Overall, these results illustrate significant heterogeneity among molecular types of AML in sensitivity to both induction chemotherapy and GO scheduling.

The question of what consolidation is required after two courses of FLAG-Ida + GO remains open. This randomized comparison showed no OS benefit from two courses of HDAC, although there was an increase in relapse risk with one consolidation course. In the nonrandomized comparison of NPM1[mut] patients who were PB PC2 MRD− after two cycles of FLAG-Ida + GO, this treatment appears sufficient with an OS of 90% and no RFS benefit for those given consolidation. If treatment is discontinued in such cases, then ongoing MRD monitoring could be used for early identification and preemptive treatment of relapse. Novel maintenance treatment approaches are of interest in this situation[22,23] and warrant investigation. FLAG-Ida combined with venetoclax has been reported to produce high rates of CR and MRD negativity in newly diagnosed AML, including patients with FLT3[mut], further supporting the ongoing evaluation of intensive induction regimens in AML.[24]

In conclusion, in this randomized trial, we saw no benefit for fractionated GO and although FLAG-Ida + GO significantly improved EFS compared with DA + GO, there was no OS benefit. In exploratory analyses, there was evidence of a survival benefit in major subgroups, including patients with NPM1 and FLT3 mutations.

## AFFILIATIONS

[1]Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
[2]Centre for Trials Research, Cardiff University, Cardiff, United Kindgom
[3]Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom
[4]School of Medicine, Cardiff University, Cardiff, United Kingdom
[5]Copenhagen University Hospital, Copenhagen, Denmark
[6]University Hospitals of Bristol and Weston NHS Trust, Bristol, United Kingdom
[7]University College London Hospitals NHS Foundation Trust, London, United Kingdom
[8]Department of Haematology, St Bartholomew's Hospital, London, United Kingdom
[9]Auckland Hospital, Auckland, New Zealand
[10]Belfast City Hospital, Belfast, United Kingdom
[11]Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
[12]The Christie NHS Foundation Trust, Manchester, United Kingdom

## CORRESPONDING AUTHOR

Nigel H. Russell, Department of Haematology, Guy's and St Thomas' Hospitals NHS Trust, London SE1 9RT, United Kingdom; e-mail: Nigel. Russell@nottingham.ac.uk.

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

## DATA SHARING STATEMENT

Access to deidentified data and supporting documentation is available via formal application to Cardiff University via the corresponding authors. Cardiff University is committed to open access to deidentified clinical trial data.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Nigel H. Russell, Mike Dennis
**Administrative support:** Leona M. Batten, Joanna Canham, Emily L. Hinson, Sophie Betteridge
**Provision of study materials or patients:** Richard Dillon, Steven Knapper, Sylvie D. Freeman, Ulrik Malthe Overgaard, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell
**Collection and assembly of data:** Nigel H. Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dillon, Steven Knapper, Leona M. Batten, Joanna Canham, Emily L. Hinson, Sophie Betteridge, Ulrik Malthe Overgaard, Amanda Gilkes, Nicola Potter, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D. Freeman
**Data analysis and interpretation:** Charlotte Wilhelm-Benartzi, Jad Othman
**Manuscript writing:** All authors
**Final approval of manuscript:** All authors
**Accountable for all aspects of the work:** All authors

## ACKNOWLEDGMENT

## REFERENCES

1. Döhner H, Wei AH, Appelbaum FR, et al: Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345-1377, 2022
2. Burnett AK, Russell NH, Hills RK, et al: Optimization of chemotherapy for younger patients with acute myeloid leukemia: Results of the medical research council AML15 trial. J Clin Oncol 31:3360-3368, 2013
3. Burnett AK, Hills RK, Milligan D, et al: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 29:369-377, 2011
4. Castaigne S, Pautas C, Terré C, et al: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 379:1508-1516, 2012
5. Lambert J, Pautas C, Terré C, et al: Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104:113-119, 2019
6. Hills RK, Castaigne S, Appelbaum FR, et al: Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986-996, 2014
7. Lambert J, Lambert J, Nibourel O, et al: MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget 5:6280-6288, 2014
8. Fournier E, Duployez N, Ducourneau B, et al: Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood 135:542-546, 2020
9. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69-79, 1999
10. Ivey A, Hills RK, Simpson MA, et al: Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374:422-433, 2016
11. Burnett AK, Hills RK, Nielsen OJ, et al: A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: Data from the UK NCRI AML17 trial. Leukemia 32:2693-2697, 2018
12. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003
13. Russell N, Wilhelm-Benartzi C, Knapper S, et al: FLAG-Ida combined with gemtuzumab ozogamicin (GO) improves event free survival in younger patients with newly diagnosed acute myeloid leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140:526-528, 2022 (suppl 1)
14. Papaemmanuil E, Gerstung M, Bullinger L, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209-2221, 2016
15. Tazi Y, Arango-Ossa JE, Zhou Y, et al: Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun 13:4622, 2022
16. Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059-2074, 2013
17. Stone RM, Mandrekar SJ, Sanford BL, et al: Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454-464, 2017
18. Tarlock K, Alonzo TA, Gerbing RB, et al: Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: A report from the Children's Oncology Group. Clin Cancer Res 22:1951-1957, 2016
19. Russell N, Wilhelm-Benartzi C, Othman J, et al: S126: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Results from the NCRI AML19 "MIDOTARG" pilot trial. Hemasphere 6:27-28, 2022
20. Rollig C, Schliemann C, Mikesch J, et al: Gemtuzumab ozogamicin plus midostaurin in combination with standard intensive induction therapy in newly diagnosed AML: Results from a phase-I study. Blood 138, 2021 (suppl 1; abstr 2324)
21. Kapp-Schwoerer S, Weber D, Corbacioglu A, et al: Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: Results from the AMLSG 09-09 trial. Blood 136:3041-3050, 2020
22. Wei AH, Döhner H, Pocock C, et al: Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526-2537, 2020
23. Döhner H, Wei AH, Roboz GJ, et al: Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood 140:1674-1685, 2022
24. DiNardo CD, Lachowiez CA, Takahashi K, et al: Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39:2768-2778, 2021

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

**Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With *NPM1* and *FLT3* Mutations**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

**Nigel H. Russell**
**Honoraria:** Jazz Pharmaceuticals, Pfizer, Astellas Pharma
**Research Funding:** Jazz Pharmaceuticals (Inst)
**Travel, Accommodations, Expenses:** Jazz Pharmaceuticals

**Richard Dillon**
**Honoraria:** AbbVie, Pfizer, Novartis, Jazz Pharmaceuticals, Astellas Pharma
**Consulting or Advisory Role:** AbbVie, Novartis, Pfizer, Jazz Pharmaceuticals
**Research Funding:** Amgen (Inst), AbbVie (Inst)

**Steven Knapper**
**Honoraria:** Jazz Pharmaceuticals
**Consulting or Advisory Role:** Novartis, Jazz Pharmaceuticals, Astellas Pharma, AbbVie
**Research Funding:** Novartis (Inst)
**Travel, Accommodations, Expenses:** Jazz Pharmaceuticals

**Joanna Canham**
**Research Funding:** Jazz Pharmaceuticals (Inst), Pfizer (Inst)

**Ulrik Malthe Overgaard**
**Consulting or Advisory Role:** Pfizer, Sobi, Alexion Pharmaceuticals
**Speakers' Bureau:** Sobi
**Travel, Accommodations, Expenses:** Sobi

**Priyanka Mehta**
**Honoraria:** Astellas Pharma, Pfizer, Jazz Pharmaceuticals, AbbVie, Servier
**Consulting or Advisory Role:** Jazz Pharmaceuticals, AbbVie
**Speakers' Bureau:** Jazz Pharmaceuticals, AbbVie, Astellas Pharma
**Travel, Accommodations, Expenses:** Jazz Pharmaceuticals

**Jamie Cavenagh**
**Employment:** GlaxoSmithKline
**Stock and Other Ownership Interests:** GlaxoSmithKline
**Honoraria:** Janssen-Cilag, Celgene, Takeda, Novartis, Amgen, AbbVie, Jazz Pharmaceuticals
**Travel, Accommodations, Expenses:** Takeda

**Claire Arnold**
**Honoraria:** Novartis Pharmaceuticals UK Limited

**Sylvie D. Freeman**
**Consulting or Advisory Role:** MPAACT
**Speakers' Bureau:** Novartis, Jazz Pharmaceuticals
**Research Funding:** Jazz Pharmaceuticals (Inst), Bristol Myers Squibb/ Celgene (Inst)
**Patents, Royalties, Other Intellectual Property:** Vyas P, Goardon N, Freeman S. (2011). US Patent Application 13/995,347. Title: Detection of Acute Myeloid Leukemia. Granted 2018 (Inst)
**Travel, Accommodations, Expenses:** BD Biosciences

**Mike Dennis**
**Research Funding:** Celgene (Inst), Daiichi Sankyo (Inst), Bio-Cancer Treatment International (Inst)

No other potential conflicts of interest were reported.

# APPENDIX 1. AML19 LIST OF SITES AND INVESTIGATORS

Aalborg Hospital: Maria Kallenbach, Marianne Severinsen; Aarhus Hospital: Mette Holm, Jan Maxwell Norgaard, Hans Beier Ommen; Aberdeen Royal Infirmary: Dominic Culligan, Jane Tighe; Addenbrooke's University Hospital: Jenny Craig, Charles Crawley, Pramila Krishnamurthy; Aintree Hospital: Walid Sadik, Jeffery Smith; Arrowe Park: Ranjit Dasgupta; Auckland City Hospital: Leanne Berkhan, Peter Bowett, Richard Doocey, Shannon Emmett, Timothy Hawkins, Nigel Patton, Lucy Pemberton; Basingstoke and North Hampshire Hospital: Alison Milne, Ashok Roy, Sylwia Simpson; Belfast City Hospital: Claire Arnold, Robert Cuthbert, Damian Finnegan, Mary Francis McMullin, Victoria Pechey; Birmingham Heartlands Hospital: Richard Lovell, Donald Milligan, Shankara Paneesha; Blackpool Victoria Infirmary: Paul Cahalin, P. Kelsey; Bradford Royal Infirmary: Sam Ackroyd, Adrian Wiliams; Bristol Haematology and Oncology Centre: Roger Evely, David Marks, Priyanka Mehta; Castle Hill Hospital: Andrew Fletcher, Maryam Al-Ani, Khalil Ahmed; Cheltenham General Hospital: Richard Lush, Adam Rye; Chesterfield Royal Hospital: Robert Cutting, Andrew Fletcher, Emma Welch, Mark Wodzinski; Christchurch Hospital: Andrew Butler, Liam Fernyhough, Peter Ganly, Steve Gibbons, Mark Smith, Ruth Spearing; Churchill Hospital, Oxford: Andy Peniket, Faye Hatcliffe; Clatterbridge Cancer Centre/The Royal Liverpool Hospital: Amit Patel, Kathrine Lindsay; Countess of Chester Hospital: Gillian Brearton, Salah Tuegar; Croydon: S. Gandhi Anna Cowley; Derriford Hospital: Adrian Copplestone, Hannah Hunter, Patrick Medd, Tim Nokes, Simon Rule, Wayne Thomas; Doncaster Royal Infirmary: Robert Cutting, Joe Joseph, Stuti Kaul, Youssef Sorour; Dunedin Hospital: Shingi Chvuka, Hilda Mangos, Annette Neylon; Forth Valley: Katrina Farrell, Hugh Edwards, Katharine Hanlon; Freeman Hospital: Tom Fail, Glan Clwyd Hospital: Margaret Goodrick, Earnest Heartin, Christine Hoyle; Gloucestershire Royal Hospital: Adam Rye; Guys Hospital: Robert Carr, Kavita Raj; Herlev Hospital: Morten Krogh Jensen; Hillingdon Hospital: Riaz Janmohamed, Richard Kaczmarski, Taku Sugai; Ipswich Hospital: Debo Ademokun, Isobel Chalmers, Andrew Hodson; James Paget Hospital: Cesar Gomez, Shala Sadullah; Kettering General hospital: Mark Kwan, Karyn Longmuir, Isaac Wilson-Morkeh; Leicester Royal Infirmary: Ann Hunter, Murray Martin; Lincoln County Hospital: Kandeepan Saravanamuttu, Gamal Sidra; Manchester Royal Infirmary: Sarah Burns, Simon Gibbs, Eleni Tholouli; Medway Maritime Hospital: Maadh Aldouri, Vivienne Andrews, Ayed Eden; Milton Keynes Hospital: Moez Dungarwalla, Denise White; Monklands Hospital: Jane Laird, Lindsey Mitchell, John Murphy, Pamela Paterson, Alaeddin Raafat; Musgrove Park Hospital: Deepak Mannari, Simon Davies, Belinda Austen, Sarah Allford, Sudhakar Kakalamudi; New Cross Hospital: Supratik Basu, Sunil Hada, Abraham Jacob, Alan MacWhonell; New Victoria Hospital: Alison McCaig; Ninewells Hospital and Medical Centre: Keith Gelly, Ron Kerr, David Meiklejohn, Sudhir Tauro; Norfolk and Norwich University Hospitals: Matthew Lawes; Northampton General Hospital: Angela Bowen, Suchitra Krishnamurthy; Nottingham University Hospitals NHS Trust: Jenny Byrne, Emma Dasgupta, Nigel Russell, Simone Stokley; Odense Hospital: Lone Friis, Claus Marcher; Palmerston North: Bart Bake; Pinderfield General Hospital: Mary Chapple, Paul Moreton, Asad Omran, Kavita Patil, David Wright; Poole Hospital: Fergus Jack, Rebecca Maddams; Queen Alexandra Hospital, Portsmouth: Robert Corser, Tanya Cranfield, Helen Dignum, Mary Ganczakowski, Christopher Jones; Queen Elizabeth Hospital, Birmingham: Charles Craddock, Paula Moss, Jim Murray; Queens Hospital: Claire Hemmaway; Raigmore Hospital: Joanne Craig, Peter Forsyth, Chris Lush; Rigshospitalet: Ole Wei Bjerrum, Niels Borregaard, Peter Kampmann, Lars Kjeldsen, Ove Juul Nielsen, Carsten Niemann, Soeren Lykke Petersen; Roskilde: Lene Udby Peter Møller; Rotherham General Hospital: Arun Alfred, Helen Barker, Richard Went; Royal Berkshire: Henri Groch, Stuart Mucklow, Rebecca Sampson; Royal Bournemouth Hospital: Joseph Chacko, Rachel Hall, Renata Walewska; Royal Cornwall Hospital: Desmond Creach, Bryson Pottinger; Royal Derby Hospital: Juanah (Jo) Addada; Royal Devon and Exeter Hospital: Malcolm Hamilton, Paul Kerr, Loretta Ngu, Claudius Rudin, Jackie Ruell; Royal Hallamshire Hospital: Chris Dalley, Harpreet Kaur, John Reilly, John Snowden; Royal Stoke Hospital: Paul Ferguson, Peter Dyer, Deepak Chandra; Royal Surrey: Johannes DeVos, Elisabeth Grey-Davies, Louise Hendry, Timothy Corbett; Royal United Hospitals Bath NHS Foundation Trust: Josephine Crowe, Christopher Knechtli, Sarah Wexler; Russells Hall Hospital: Savio Fernandes, Jeff Neilson; Salford Royal Hospital: John Houghton, Simon Jowitt, Rowena Thomas-Dewing, Mark Williams, Sonya Zaman; Salisbury Hospital NHS Foundation: Jonathan Cullis, Tamara Everington, Effie Grand; Sandwell Hospital: Yasmin Hasan, Richard Murrin, Farooq Wandoo; Singleton Hospital: Saad Ismail, Unmesh Mohite, Hamdi Sati; Southampton University Hospital: Matthew Jenner, Kim Orchard, Deborah Richardson; St Bartholomew's Hospital: Kayleigh McCloskey; St George's Hospital: Kate Xu Chin, Neoh Fenella Willis, Amit Sud; St Helens Hospital: Maged Gharib, Toby Nicholson; St James University Hospital: David Bowen; St Richards: Sarah Janes; Stoke Mandeville Hospital: Helen Eagleton, Anne-Marie O'Hea, Jonathan Pattinson; Sunderland Royal Hospital: Victoria Hervey, Simon Lyons, Scott Marshall, Annette Nicolle; The Beatson WOS Cancer Centre: Maria Vavyla, Jordan Burgess; The Christie: Tim Somervaille, Sven Somerfield, Mohd Mamat, Jo Tomlins, Sana Salesh; The James Cook University Hospital: Marianna David, Jamie Maddox, Diane Plews, Ray Dang; The Royal Marsden: Mike Potter, Lauren Ellis, Emma Nicholson, Sally Keat, Thubeena M Ahmed Alhassani; The Royal Oldham Hospital: Farahn Anjum, Poulami Chatterjee, Atanas Stanchev, Jayne Peters, Sarah Lindsay-Holmes Srividhya, Senthil S Chodhouri; Torbay District General Hospital: Heather Eve, Steve Smith, Patrick Roberts, Nicholas Rymes, Rui Zhao New Oo; University College London Hospitals: Kirit Ardeshna, Piers Blombery, Asim Khwaja, David Linch, Rakesh Popat, Andres Virchis, Kwee Yong; University Hospital Ayr: Victoria McIntyre, Gillian Horne; University Hospital Coventry: Syed Bokhari, Anton Borg, Oliver Chapman, Beth Harrison, Nicholas Jackson, Shailesh Jobanputra, Mekkali Narayanan, Peter Rose; University Hospital Crosshouse: Hajer Oun, Matthew Powell, Julie Gilles, Alison Laing, Ian Devanny, Gillian Horne, Lea Haskins, Paul Micallef-Eynaud, Peter Maclean; University Hospital of Wales: Caroline Alvares, Jonathan Kell, Steve Knapper; Victoria Hospital, NHS FIFE: Kerri Davidson, Lorna McLintock, Stephen Rogers, Peter Williamson; Waikato Hospital: Gillian Corbett, Hugh Goodman, Shahid Islam, Humphrey Pullon; Western General Hospital: Peter Johnson, P.H. Roddie; Worcestershire Royal Hospital: Elizabeth Maughan, Juliet Mills, Salim Shafeek; Worthing Hospital: Santosh Narat; Wycombe Hospital: Robin Aitchison, Jonathan Pattinson; York Hospital: Lee Bond, Laura Munro; Ysbyty Gwynedd: David Edwards.